Fusion Antibodies Plc (LSE:FAB), the antibody discovery and engineering specialist, announced a contract worth more than £85,000 with a US-based specialty division of a global pharmaceutical company on 22 October 2026. The award came a week after an AGM statement on 15 October in which the company reported lower first-half Revenue and said it was reviewing its Working Capital requirements, with cash reserves of about £135,000.
Company Overview
Fusion Antibodies provides contract services to pharmaceutical and biotechnology companies, including antibody discovery, cell line development, transient gene expression and structural studies such as cryogenic electron microscopy. It also runs grant-funded projects with Queen's University Belfast.
The company has also developed OptiMAL, a proprietary antibody discovery platform that it launched commercially in December 2025. LSE:FAB is led by chief executive Dr Adrian Kinkaid. Combining service work with its own platform allows the group to serve customers who need individual project support as well as those interested in access to a technology for discovering antibodies.
Transient gene expression is a technique used to produce proteins, such as antibodies, quickly without creating a stable cell line, which makes it useful when a customer needs material for early testing. Cryogenic electron microscopy is used to visualise the three-dimensional structure of molecules, and structural information of that kind can help guide the design of antibody drugs.
Latest Developments
The October contract covers transient gene expression and a cryogenic electron microscopy study. The company described the work as repeat Business and technologically complex, supporting its aim of working with larger pharmaceutical clients. It expects to complete the project within the current financial year.
The AGM statement set out the trading position for the first half of the 2027 financial year. Revenue was £457,000, compared with £838,000 a year earlier, according to the unaudited figures, and gross Margin was 10% compared with 30%. The company has introduced a recruitment freeze while it reviews working capital.
On the development side, it reported in-vivo results for its DR5 therapeutic antibody programme in colorectal cancer studies and said negotiations were continuing over further use of OptiMAL by the US National Cancer Institute.
DR5 is a target that the company is studying with an antibody approach, and the programme is supported by grant funding in Partnership with Queen's University Belfast. The US National Cancer Institute discussions relate to further use of OptiMAL, which is the platform the company launched in December 2025.
Fusion has also been building its Patent portfolio, with a Canadian patent for OptiMAL announced on 9 September 2026, acceptance of an Australian patent in August, and grants in Japan alongside existing US patents. A new customer-focused website was launched on 5 October. Patent protection matters for a platform company because it helps safeguard the technology behind the service as it is offered to more customers across different countries.
Financial Picture
Final results published on 14 September 2026 covered the year to 31 March 2026. Revenue rose to about £2.1m from £1.97m, helped by an intellectual property transfer to Finn Therapeutics worth £250,000, with payment expected in the 2027 financial year after a Finn fundraise. Gross margin was reported at 53%, up from 22%. The operating loss narrowed to £1.13m, and other Operating Income of £872,000 came mainly from a grant programme. Year-end cash was £1.04m. A grant-funded DR5 project with the university could bring in up to £545,000. No Dividend was reported.
The improvement in gross margin from 22% to 53% in the full year shows how the mix of projects can influence profitability. The movement to 10% in the first half of the current year illustrates the same point from the other direction, and project timing is an important Factor for the company.
The financial year to 31 March 2026 also included other operating income of £872,000, mainly from a grant programme, which shows the role that grant funding plays alongside customer contracts in the company's activities.
Sector and index Context
Fusion is one of the smaller life sciences companies in the FTSE AIM All Share Index. Small contract service providers in the sector have seen Demand vary with biotech funding conditions, which makes revenue from individual projects uneven from period to period.
Customers in this area include pharmaceutical and biotechnology companies at various stages of drug development, and their spending tends to follow their own funding and pipeline decisions.
In this setting, repeat business from a global pharmaceutical group, such as the October award, is a useful indicator of customer relationships for LSE:FAB, particularly where the work is technically complex and involves specialised techniques.
Factors to Monitor
Cash and working capital are the central themes while the company completes its review. Revenue depends on a small number of contracts, and gross margin can move with the mix of projects. Commercial uptake of OptiMAL and the outcome of the discussions with the National Cancer Institute will be followed with interest.
What to Watch Next
Market participants will look for the outcome of the working capital review, any funding announcements, the half-year report for the six months to 30 September 2026, further contract wins and progress on OptiMAL licensing and the DR5 programme from LSE:FAB.






Please wait processing your request...